{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:19:59Z","timestamp":1792736399448,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.vaccine.2009.07.039","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T08:56:19Z","timestamp":1249376179000},"page":"5885-5895","source":"Crossref","is-referenced-by-count":47,"title":["Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines"],"prefix":"10.1016","volume":"27","author":[{"given":"Patricia L.","family":"Earl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"VanCott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh Anne","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"McCutchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"Birx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson L.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Marovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine H.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.07.039_bib1","unstructured":"UNAIDS. The AIDS Epidemic Today. http:\/\/www.unaids.org; 2008."},{"issue":"October (7213)","key":"10.1016\/j.vaccine.2009.07.039_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barouch","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.07.039_bib3","unstructured":"HVTN. The Pipeline Project: HVTN vaccines in development. http:\/\/chi.ucsf.edu\/vaccines; 2008."},{"key":"10.1016\/j.vaccine.2009.07.039_bib4","unstructured":"IAVI. Ongoing Trials of Preventive HIV Vaccines. http:\/\/www.iavireport.org\/secials\/OngoingTrialsofPreventiveHIVVaccines.asp; 2007."},{"key":"10.1016\/j.vaccine.2009.07.039_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Passage history, properties, and applicability of the Attenuated Vaccinia Virus Strain MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2009.07.039_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara stra: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"issue":"May","key":"10.1016\/j.vaccine.2009.07.039_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib8","first-page":"365","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in nonhuman mammalian cell line","volume":"244","author":"Carroll","year":"1997","journal-title":"Virology"},{"issue":"February","key":"10.1016\/j.vaccine.2009.07.039_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"issue":"May","key":"10.1016\/j.vaccine.2009.07.039_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib11","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2009.07.039_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2007.02.041","article-title":"Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate","volume":"366","author":"Earl","year":"2007","journal-title":"Virology"},{"issue":"November (10)","key":"10.1016\/j.vaccine.2009.07.039_bib13","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/592507","article-title":"Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara","volume":"198","author":"Sandstrom","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.039_bib14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.039_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, eigenschaften und verwendung des attenuieten vaccinia-stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2009.07.039_bib16","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2009.07.039_bib17","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2009.07.039_bib18","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","article-title":"Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis","volume":"24","author":"Gilbert","year":"2006","journal-title":"Vaccine"},{"issue":"January","key":"10.1016\/j.vaccine.2009.07.039_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.82493-0","article-title":"Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction","volume":"88","author":"Hanke","year":"2007","journal-title":"J Gen Virol"},{"issue":"March (11)","key":"10.1016\/j.vaccine.2009.07.039_bib20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.vaccine.2006.11.016","article-title":"Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity","volume":"25","author":"Peters","year":"2007","journal-title":"Vaccine"},{"issue":"November (47)","key":"10.1016\/j.vaccine.2009.07.039_bib21","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"issue":"November (9653)","key":"10.1016\/j.vaccine.2009.07.039_bib22","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"November (9653)","key":"10.1016\/j.vaccine.2009.07.039_bib23","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2009.07.039_bib24","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1128\/JVI.76.12.6138-6146.2002","article-title":"Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime\/recombinant modified vaccinia virus Ankara vaccine","volume":"76","author":"Amara","year":"2002","journal-title":"J Virol"},{"issue":"August (15)","key":"10.1016\/j.vaccine.2009.07.039_bib25","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.76.15.7625-7631.2002","article-title":"Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA\/MVA vaccines","volume":"76","author":"Amara","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib26","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.039_bib27","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1128\/JVI.74.9.4236-4243.2000","article-title":"Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies","volume":"74","author":"Stittelaar","year":"2000","journal-title":"J Virol"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2009.07.039_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/viro.2000.0564","article-title":"Evaluation of recombinant vaccinia virus\u2014measles vaccines in infant rhesus macaques with preexisting measles antibody","volume":"276","author":"Zhu","year":"2000","journal-title":"Virology"},{"issue":"April (5514)","key":"10.1016\/j.vaccine.2009.07.039_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.1058915","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2009.07.039_bib30","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1128\/JVI.75.11.5151-5158.2001","article-title":"Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination","volume":"75","author":"Barouch","year":"2001","journal-title":"J Virol"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2009.07.039_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/viro.2001.1345","article-title":"Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model","volume":"294","author":"Earl","year":"2002","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.039_bib32","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/JVI.74.6.2740-2751.2000","article-title":"Comparative efficacy of recombinant modified vaccinia virus ankara expressing simian immunodeficiency virus (SIV) gag-Pol and\/or env in macaques challenged with pathogenic SIV","volume":"74","author":"Ourmanov","year":"2000","journal-title":"J Virol"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2009.07.039_bib33","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1128\/JVI.80.10.4717-4728.2006","volume":"80","author":"Goonetilleke","year":"2006","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.07.039_bib34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1089\/aid.2007.0098","article-title":"HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses","volume":"23","author":"Finnefrock","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.07.039_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2009.07.039_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/0889222041725235","article-title":"HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania","volume":"20","author":"Arroyo","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"September (13)","key":"10.1016\/j.vaccine.2009.07.039_bib37","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/00002030-200209060-00015","article-title":"Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants","volume":"16","author":"Dowling","year":"2002","journal-title":"Aids"},{"issue":"November (17)","key":"10.1016\/j.vaccine.2009.07.039_bib38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/088922202320886325","article-title":"Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate","volume":"18","author":"Harris","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"December (24)","key":"10.1016\/j.vaccine.2009.07.039_bib39","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.07.039_bib40","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1084\/jem.20072457","article-title":"Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients","volume":"205","author":"Goepfert","year":"2008","journal-title":"J Exp Med"},{"issue":"December (7018)","key":"10.1016\/j.vaccine.2009.07.039_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature03113","article-title":"Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA","volume":"432","author":"Kiepiela","year":"2004","journal-title":"Nature"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2009.07.039_bib42","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1128\/JVI.02455-07","article-title":"HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load","volume":"82","author":"Rousseau","year":"2008","journal-title":"J Virol"},{"issue":"January (3)","key":"10.1016\/j.vaccine.2009.07.039_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0b013e3282f29491","article-title":"Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes","volume":"22","author":"Yang","year":"2008","journal-title":"Aids"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2009.07.039_bib44","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.039_bib45","first-page":"1","article-title":"Preparation of cell cultures and vaccinia virus stocks","volume":"vol. 16","author":"Earl","year":"1998"},{"key":"10.1016\/j.vaccine.2009.07.039_bib46","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1073\/pnas.83.21.8122","article-title":"Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase","volume":"83","author":"Fuerst","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (5263)","key":"10.1016\/j.vaccine.2009.07.039_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"issue":"June (13)","key":"10.1016\/j.vaccine.2009.07.039_bib48","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1073\/pnas.96.13.7496","article-title":"Constitutive cell surface association between CD4 and CCR5","volume":"96","author":"Xiao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.07.039_bib49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/viro.1993.1151","article-title":"The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s)","volume":"193","author":"Broder","year":"1993","journal-title":"Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib50","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.272.5270.1955","article-title":"CC CKR5: a rantes, mip-1 alpha, mip-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1","volume":"272","author":"Alkhatib","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.07.039_bib51","unstructured":"Chakrabarti S. unpublished."},{"key":"10.1016\/j.vaccine.2009.07.039_bib52","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1073\/pnas.92.19.9004","article-title":"Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages","volume":"92","author":"Broder","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.07.039_bib53","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/JVI.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","author":"Earl","year":"1990","journal-title":"J Virol"},{"issue":"June\u2013July (6124)","key":"10.1016\/j.vaccine.2009.07.039_bib54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/327716a0","article-title":"Site-specific mutagenesis of AIDS virus reverse transcriptase","volume":"327","author":"Larder","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.07.039_bib55","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.00687-09","article-title":"Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selections","volume":"83","author":"Wyatt","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0264-410X(99)00257-1","article-title":"Priming and boosting immunity to respiratory syncytial virus by recombinant replicaiton-defective vaccinia virus MVA","volume":"18","author":"Wyatt","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.039_bib57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal mode","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2009.07.039_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines","volume":"26","author":"Wyatt","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.039_bib59","doi-asserted-by":"crossref","unstructured":"Earl PL, Moss B, Wyatt LS, Carroll MW. Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol 2001;Unit 16 7 [Chapter 16].","DOI":"10.1002\/0471142727.mb1617s43"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2009.07.039_bib60","doi-asserted-by":"crossref","first-page":"8964","DOI":"10.1073\/pnas.86.22.8964","article-title":"Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector","volume":"86","author":"Karacostas","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2009.07.039_bib61","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1128\/JVI.68.9.5411-5422.1994","article-title":"Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation","volume":"68","author":"Nussbaum","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/JVI.62.1.139-147.1988","article-title":"In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity","volume":"62","author":"Willey","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib63","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1128\/JVI.68.5.3015-3026.1994","article-title":"Native oligomeric forms of human immunodeficiency virus type 1 envelope glycoprotein elicit a diverse array of monoclonal antibody reactivities","volume":"68","author":"Earl","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib64","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1128\/JVI.66.11.6547-6554.1992","article-title":"Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelpe sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism","volume":"66","author":"Chesebro","year":"1992","journal-title":"J Virol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2009.07.039_bib65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1006\/viro.1993.1424","article-title":"Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene","volume":"195","author":"Yuwen","year":"1993","journal-title":"Virology"},{"issue":"June (7)","key":"10.1016\/j.vaccine.2009.07.039_bib66","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00002030-199606001-00015","article-title":"HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice","volume":"10","author":"Doe","year":"1996","journal-title":"Aids"},{"issue":"November (18)","key":"10.1016\/j.vaccine.2009.07.039_bib67","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/QAD.0b013e328010ad0c","article-title":"Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes","volume":"20","author":"Xu","year":"2006","journal-title":"Aids"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.07.039_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1128\/JVI.76.1.185-194.2002","article-title":"Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene","volume":"76","author":"Casimiro","year":"2002","journal-title":"J Virol"},{"issue":"July (13)","key":"10.1016\/j.vaccine.2009.07.039_bib69","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.039_bib70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1128\/JVI.75.2.645-653.2001","article-title":"Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus Type 1 gp140","volume":"75","author":"Earl","year":"2001","journal-title":"J Virol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.07.039_bib71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.2007.0205","article-title":"Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C","volume":"24","author":"Burgers","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2009.07.039_bib72","unstructured":"Bakari M, Mhalu F, Aboud S, Nilsson C, Francis J, Janabi M., et al. Safety and immunogenicity of an HIV-1 DNA plasmid vaccine boosted with HIV-1 MVA among police officers in Dar es Salaam, Tanzania. Oral presentation, AIDS Vaccine 2008, Cape Town, South Africa; 2008."},{"key":"10.1016\/j.vaccine.2009.07.039_bib73","doi-asserted-by":"crossref","unstructured":"Currier J, Ngauy V, Cox J, Earl P, Moss B, Robb M, et al. Comprehensive characterization of cellular immune responses induced by modified vaccinia Ankara (MVA)-HIV-1 in a phase I randomized, controlled trial. Oral presentation, AIDS Vaccine 2008, Cape Town, South Africa; 2008.","DOI":"10.1186\/1742-4690-6-S3-O27"},{"key":"10.1016\/j.vaccine.2009.07.039_bib74","unstructured":"Goepfert PA, Robinson H, Qin L, Hay C, Frey S, Blattner W, et al. GeoVax clade B DNA\/MVA vaccine induces persistent multifunctional immune responses when administerd to healthy HIV seronegative adulsts (HVTN 065). Poster presentation, AIDS Vaccine 2008, Cape Town, South Africa; 2008."},{"issue":"March (3)","key":"10.1016\/j.vaccine.2009.07.039_bib75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat Med"},{"issue":"January (7225)","key":"10.1016\/j.vaccine.2009.07.039_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature07469","article-title":"Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys","volume":"457","author":"Liu","year":"2009","journal-title":"Nature"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2009.07.039_bib77","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2009.07.039_bib78","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2003-04-1203","article-title":"Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy","volume":"103","author":"Harari","year":"2004","journal-title":"Blood"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2009.07.039_bib79","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/526786","article-title":"Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy","volume":"197","author":"Pereyra","year":"2008","journal-title":"J Infect Dis"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2009.07.039_bib80","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1016\/j.vaccine.2006.01.017","article-title":"Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2009.07.039_bib81","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","article-title":"Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity","volume":"27","author":"Gudmundsdotter","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09010500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09010500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T04:56:53Z","timestamp":1590037013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09010500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":81,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0264410X09010500"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}